Dong Yan^1,#, Chunxiao Li^2,#, Yantong Zhou², Xue Yan¹, Weihua Zhi¹, Haili Qian^2,*, Yue Han^1,*

Oncologie, Vol.24, No.1, pp. 101-111, 2022, DOI:10.32604/oncologie.2022.020357

Abstract Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic to identify candidate drugs that might hold promise when used in combination with sorafenib. Our results revealed that… More >

Beifen Dai^1,#, Zhihao Xu^2,#, Hongjue Li³, Bo Wang³, Jinsong Cai¹, Xiaomo Liu^4,*

Oncologie, Vol.24, No.1, pp. 113-130, 2022, DOI:10.32604/oncologie.2022.020259

Abstract Large-scale genomic studies are important ways to comprehensively decode the human genomics, and provide valuable insights to human disease causalities and phenotype developments. Genomic studies are in need of high throughput bioinformatics analyses to harness and integrate such big data. It is in this overarching context that artificial intelligence (AI) offers enormous potentials to advance genomic studies. However, racial bias is always an important issue in the data. It is usually due to the accumulation process of the dataset that inevitability involved diverse subjects with different races. How can race bias affect the outcomes of AI methods? In this work,… More >

Jiayi Huang¹, Xue Bai¹, Xiaofeng Xie¹, Liping Chen¹, Xiaofeng Lan¹, Qiuyi Zhang¹, Lin Song¹, Pengjiao Hong^2,3, Caiwen Du^1,*

Oncologie, Vol.24, No.1, pp. 131-145, 2022, DOI:10.32604/oncologie.2022.019881

Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences… More >

Federico Cappellacci^*, Gian Luigi Canu, Stefano Piras, Giacomo Anedda, Pietro Giorgio Calò, Fabio Medas

Oncologie, Vol.24, No.1, pp. 35-50, 2022, DOI:10.32604/oncologie.2022.020864

Abstract Thyroid cancer is the fifth most common cancer in the USA, with differentiated subtype accounting for more than 95% of neoplasm. Surgery remains the mainstay of treatment, either with lobectomy or total thyroidectomy. In the last decades, many technological innovations have been introduced in this field. The aim of this review is to illustrate the most recent advances regarding the classical surgical approach, particularly regarding hemostatic devices, parathyroid identification with fluorescence systems, intraoperative identification of lymph node metastases, and intraoperative neuromonitoring. More >

Hiba Alzoubi¹, Alameen Alsabbah², Rosario Caltabiano³, Giuseppe Broggi^3,*

Oncologie, Vol.24, No.1, pp. 51-63, 2022, DOI:10.32604/oncologie.2022.020890

Abstract The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) improved our understanding of the brain neoplasm biology. In more details, differences between diffuse gliomas that primarily occur in adults and those that primarily occur in children have been identified by the terms “adult-type” and “pediatric-type” diffuse gliomas. More importantly, both diagnostic and grading criteria for adult-type diffuse astrocytomas have been modified, by adopting novel molecular markers: diffuse astrocytomas, IDH-mutant have been grouped into a single entity and graded as CNS WHO grades 2, 3, or 4, with the assignment of Grade 4 in the… More >

Ismail Bozkurt^1,*, Baris Yasar¹, Mehmet Baran Uslu², Nazan Bozdogan³

Oncologie, Vol.24, No.1, pp. 163-171, 2022, DOI:10.32604/oncologie.2022.019263

Abstract Malignant melanoma caused by malignant transformation of melanocytes is associated with high mortality and is difficult to manage. Metastasis is not uncommon (up to 31% of all cases) and is closely associated with a poor prognosis. Although rare (4–5%), extracutaneous melanoma has been reported; however, primary malignant melanoma of the sacrum is extremely rare (only three case reports to date). Here, we present a 51-year-old patient who underwent surgical treatment for a lesion of the spinal canal and associated bony structures; extensive aggressive resection was required. She underwent partial sacrectomy and lumbo-iliac fixation (to maintain spinal stability). Pathology revealed malignant… More >

Jean-Claude Ferrandez^1,*, Pierre-Henri Ganchou², Serge Theys³, Maria Torres-Lacomba⁴, Daniel Serin¹

Oncologie, Vol.24, No.1, pp. 25-33, 2022, DOI:10.32604/oncologie.2022.018110

Abstract Upper limb lympedema is a frequent consequence of breast cancer treatment. The International Society of Lymphology recommends physical therapy for lymphedema management. This treatment includes a combination of manual lymphatic drainage and high-compression bandaging. Actually, the effectiveness of manual lymphatic drainage remains an area of controversy, especially because of the many different techniques called “manual lymphatic drainage” since 1930. The purpose of this review was to emphasise the efficacy of these different techniques according to physiological data and evidence-based practice. To improve the manual lymphatic drainage efficiency, the pressure, sometimes important, should be tailored to each edema and the techniques… More >

Hangxing Wang^1,#, Jingyun Fang^1,#, Yujiao Wang^2,#, Shuo Li², Zirui Wang², Wei He², Nan Wang¹, Shuang Luo¹, Huimei Zou^3,*, Fan Zhang^4,5,*

Oncologie, Vol.24, No.1, pp. 65-83, 2022, DOI:10.32604/oncologie.2022.021863

Abstract Lung cancer is the most common malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) accounts for the vast majority of cases. At present, its main treatment methods are still traditional surgery, radiotherapy and chemotherapy, with disadvantages such as a high recurrence rate and limited effectiveness. Therefore, a new, better treatment method is urgently needed. Gene editing technology, as a new genetic engineering approach, has shown great potential in gene research, gene therapy and genetic improvement. It has also emerged as a promising treatment for lung cancer. This paper reviews the current… More >

Elsa Maitre, Xavier Troussard^*

Oncologie, Vol.24, No.1, pp. 3-24, 2022, DOI:10.32604/oncologie.2022.021490

Abstract Hairy cell leukemia (LT) accounts for 2% of all leukemias. The diagnosis is based on the presence in the blood and/ or the marrow of hairy cells expressing CD103, CD123, CD11c and CD25. The BRAF^V600E mutation, a molecular marker of the disease, is present in more than 80% of cases. LT should be distinguished from other chronic B-cell lymphoproliferative disorders, including the variant form of hairy cell leukemia (HCL-V) and diffuse splenic red pulp lymphoma (DSRPL). Progress has recently been made in the management of patients. The purine analogues (PNAs) in monotherapy, deoxycoformycin (DCF) or 2-chloro-deoxyadenosine (CDA), remain the first-line… More >

Daniel Serin

Oncologie, Vol.24, No.1, pp. 1-2, 2022, DOI:10.32604/oncologie.2022.020553

Abstract This article has no abstract. More >